ALK and lung carcinoma: Evaluation of targeted treatment for a mutational subtype of NSCLC accounted for most SAS approvals in lung cancer and, hence, was deemed as “rare.” However, the mutational subtypes of EGFR, ALK rearrangement, and ROS-1 constitute approximately 17%, 7%, and 2% of all NSCLC, respectively (12).